Telehealth GLP-1 programs and traditional in-person prescribing aren't better or worse — they're different tools for different situations. Understanding those differences can save you weeks of waiting, hundreds of dollars, and the frustration of choosing the wrong path for your needs.
Speed: Telehealth Wins, Decisively
The average wait time for a new patient appointment with a primary care physician in the U.S. is 26 days, according to Merritt Hawkins' latest survey data. Add the time to get labs drawn, wait for results, and schedule a follow-up to discuss GLP-1 options, and you're looking at 4–8 weeks before receiving your first dose.
Telehealth platforms compress this timeline dramatically. The fastest platforms can complete an evaluation and ship medication within 2–3 business days. Even slower platforms typically deliver within 7–10 days. For patients who've already decided they want GLP-1 treatment and meet the clinical criteria, this speed advantage is significant.
Timeline Comparison
In-person path: 4–8 weeks from first call to first dose. Telehealth path: 3–10 days from signup to first dose. The gap is driven by appointment availability, lab turnaround, and pharmacy fulfillment.
Cost: It Depends on Your Insurance
If you have insurance that covers FDA-approved GLP-1 medications for weight loss — and you can navigate the prior authorization process — the in-person path may be cheaper out-of-pocket. Insurance coverage for Wegovy and Zepbound has expanded in 2026, with 44% of large employers now covering weight loss medications.
If you're paying cash, telehealth platforms offering compounded medications are typically far more affordable. Brand-name Wegovy runs $1,349+ per month at list price. Compounded semaglutide through telehealth platforms typically ranges from $149 to $350 per month, depending on dose and provider.
| Provider | Starting Price | Type | Speed | Link |
|---|---|---|---|---|
| Embody | $149/mo | Compounded sema | 3–5 days | Visit ↗ Paid link |
| Gala Health | $179/mo | Compounded sema/tirz | 5–7 days | Visit ↗ Paid link |
| Yucca Health | $146/mo | Compounded sema | 5–7 days | Visit ↗ Paid link |
| Sesame Care | Varies | Brand-name only | Varies by pharmacy | Visit ↗ Paid link |
Quality of Care: More Nuanced Than You'd Think
The assumption that in-person care is automatically higher quality than virtual care doesn't hold up to scrutiny. A well-run telehealth platform with board-certified obesity medicine physicians, structured titration protocols, and regular follow-ups can deliver care that equals or exceeds what you'd get from a general practitioner who prescribes GLP-1s as a small part of their practice.
The risk with telehealth is at the low end of the market — platforms that substitute a quick questionnaire for a real medical evaluation, don't offer follow-up, or prescribe high doses without titration. The risk with in-person care is that many PCPs lack specialized obesity medicine training and may not be up to date on the latest protocols.
Continuity of Care
In-person providers have an advantage in continuity — you see the same doctor, they know your history, and they can integrate GLP-1 treatment with your broader health management. Some telehealth platforms also assign a dedicated provider, but others rotate clinicians, which can lead to inconsistent care.
If continuity matters to you, ask before signing up: "Will I see the same provider at every check-in?" The answer should be yes, or at minimum, your full chart should be reviewed before each encounter regardless of which clinician you see.
When In-Person Is the Better Choice
Go the in-person route if you have complex comorbidities (type 2 diabetes requiring insulin adjustment, severe cardiovascular disease, history of pancreatitis), if your insurance covers brand-name GLP-1s with manageable copays, if you prefer hands-on injection training from a nurse, or if you want your weight management integrated with your existing care team.
When Telehealth Is the Better Choice
Choose telehealth if you're an otherwise healthy adult who meets BMI criteria, if you're paying cash and need affordable access, if your local providers have long wait times, if you live in a rural area with limited obesity medicine specialists, or if you value convenience and are comfortable with virtual communication.
Enhance MD
Board-certified providers, comprehensive virtual evaluations.
⚠️ Compounded medications are not FDA-approved.
The Hybrid Approach
Increasingly, patients are combining both. They use a telehealth platform for the initial prescription and fast access, then loop in their PCP for lab monitoring and long-term oversight. This isn't just pragmatic — it's good medicine. Your primary care doctor should know you're on a GLP-1, regardless of who prescribed it, so they can monitor for interactions, track metabolic markers, and adjust your broader treatment plan.
Key Takeaway
The best path isn't telehealth or in-person — it's whichever gets you quality care without unnecessary barriers. For most cash-pay patients in 2026, telehealth is faster and cheaper. For insured patients with complex health histories, in-person may be more appropriate.